IntelliPharmaCeutics International (TSXV:IPCI) ROE % Adjusted to Book Value : 0.00% (As of Aug. 2023)

View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International ROE % Adjusted to Book Value?

IntelliPharmaCeutics International's ROE % for the quarter that ended in Aug. 2023 was 0.00%. IntelliPharmaCeutics International's PB Ratio for the quarter that ended in Aug. 2023 was N/A. IntelliPharmaCeutics International's ROE % Adjusted to Book Value for the quarter that ended in Aug. 2023 was N/A.

IntelliPharmaCeutics International ROE % Adjusted to Book Value Historical Data

The historical data trend for IntelliPharmaCeutics International's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International ROE % Adjusted to Book Value Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-404.15

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of IntelliPharmaCeutics International's ROE % Adjusted to Book Value

For the Biotechnology subindustry, IntelliPharmaCeutics International's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IntelliPharmaCeutics International's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's ROE % Adjusted to Book Value falls into.

IntelliPharmaCeutics International ROE % Adjusted to Book Value Calculation

IntelliPharmaCeutics International's ROE % Adjusted to Book Value for the fiscal year that ended in Nov. 2022 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

IntelliPharmaCeutics International's ROE % Adjusted to Book Value for the quarter that ended in Aug. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	0.00%	/	N/A
	=	N/A

IntelliPharmaCeutics International ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

IPCIF:USA I4AA:Germany

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines